Aim: The purpose of the present study was to evaluate the clinical value of the rapid strip test of urinary adipsin for the quick diagnosis of pre-eclampsia.
Methods: In a multicenter diagnostic test study, we studied the diagnostic accuracy of the rapid strip test of urinary adipsin in women presenting with pre-eclampsia. A total of 204 pre-eclampsia patients and 254 healthy pregnant women were recruited for this study, respectively. The rapid strip test of urinary adipsin was used to detect the adipsin in the urine of each patient.
Results: The diagnostic value of the rapid strip test of urinary adipsin for pre-eclampsia was demonstrated by its high sensitivity and specificity (95.10% and 97.64%, respectively). The diagnostic accuracy was 96.51%. The consistency analysis showed that the kappa value was 0.93 compared with the gold standard diagnosis of pre-eclampsia.
Conclusion: The rapid strip test of urinary adipsin is a non-invasive test for the diagnosis of pre-eclampsia with high sensitivity and specificity. It could help the quick diagnosis of pre-eclampsia in clinical practice greatly.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jog.13156 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urinary complement factor D is increased in primary malignant hypertension: a single-center, cross-sectional study.
Sci Rep
July 2024
Department of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, China.
Kidney injury is one of the detrimental consequences of primary malignant hypertension (pMHTN). There is a paucity of non-invasive biomarkers to enhance diagnosis and elucidate the underlying mechanisms. This study aims to explore urine protein biomarkers for pMHTN associated renal damage.
View Article and Find Full Text PDFUrinary markers of the alternative and lectin complement pathway are increased in IgA vasculitis nephritis.
Clin Kidney J
December 2023
Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Background: IgA vasculitis (IgAV) is the most common form of childhood vasculitis. Nephritis (IgAVN) occurs in 50% of patients and 1-2% progress to chronic kidney disease stage 5. The pathophysiology of nephritis remains largely unknown, but recent evidence suggests that the complement system may be involved.
View Article and Find Full Text PDFBaseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Am J Nephrol
January 2023
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Article Synopsis
- C3 glomerulopathy (C3G) is a rare kidney disease caused by issues in the complement system, specifically the alternative pathway, and the study aimed to analyze biomarkers in patients participating in phase 2 trials of danicopan, a factor D inhibitor.
- Twenty-nine patients were evaluated, revealing systemic activation of the complement pathway with significant correlations between various complement biomarkers and kidney health metrics, such as eGFR and proteinuria.
- The findings highlight strong relationships between complement biomarkers and kidney function/histology, potentially enhancing the understanding and classification of C3G patients.
Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Front Immunol
November 2021
Department of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Article Synopsis
- Complement factor B (FB) mutant variants lead to excessive complement activation associated with kidney diseases like aHUS, C3 glomerulopathy, and MPGN, with current treatments mainly focused on aHUS.
- This study investigates three FB missense mutations (D371G, E601K, I242L) found in aHUS and MPGN patients, revealing that certain mutations can cause hemolysis of sheep red blood cells.
- The FD inhibitor danicopan successfully reduced complement overactivation and hemolysis by blocking the cleavage of FB in patient serum and preventing release of harmful components from glomerular endothelial cells, suggesting it could be a potential treatment strategy for these kidney diseases.
C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice.
JCI Insight
May 2020
Molecular Otolaryngology and Renal Research Laboratories, and.
Therapeutic complement inhibition is a major focus for novel drug development. Of upstream targets, factor D (FD) is appealing because it circulates in plasma at low concentrations and has a single function: to cleave factor B to generate C3 convertase of the alternative pathway (AP). Mice with a targeted deletion of factor H (FH; Cfh-/- mice) develop C3 glomerulopathy (C3G) due to uncontrolled AP activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!